Recently, Tianjin Tianyao Pharmaceuticals Co.,Ltd. announced that it had received the Notice of Approval for the Launching Application of Chemical APIs for Travoprost approved and issued by National Medical Products Administration, and the preparation corresponding to Travoprost was mainly Travoprost eye drops. Tianjin Tianyao Pharmaceuticals Co.,Ltd. has achieved full coverage of this variety of "APIs+preparations" in China, and the domestic market space is expected to be further expanded.

According to the announcement, travoprost is used to reduce the elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. According to the national enlarged hospital data of MENET (including urban public hospitals, county-level public hospitals, urban community hospitals and township hospitals), the domestic sales of Travoprost Eye Drops in 2021 and 2022 were 90.68 million yuan and 106.28 million yuan respectively. Travoprost preparations and APIs have successively been approved for launching, which will further enrich the company's product structure, give full play to the advantages of raw material preparation integration, and boost the company's business development.

It is understood that the layout of the whole industrial chain of "APIs+preparations" is one of the main modes for industrial upgrading of chemical enterprises at present. As a leading enterprise of steroid hormone APIs in China, Tianjin Tianyao Pharmaceuticals Co.,Ltd. takes the lead in the industry in industrial upgrading. At present, the company has extended the advantages of APIs to preparation products, broken through the upstream and downstream industrial chains, and has become a dominant enterprise in the whole industrial chain of "APIs plus preparations" with steroid hormones and amino acids as the core in domestic.

In recent years, relying on its advantages in steroid hormones and amino acid APIs integration, Tianjin Tianyao Pharmaceuticals Co.,Ltd. has made every effort to carry out new drug registration, qualification certification and consistency evaluation at home and abroad, and accelerated the landing of relevant achievements. Up to now, the company has more than 20 products passed the consistency evaluation one after another; more than ten products have obtained the Drug Registration Certificate. Many corticosteroid APIs such as prednisone, spironolactone, dexamethasone, methylprednisolone of Tianjin Tianyao Pharmaceuticals Co.,Ltd. have passed the FDA certification in the United States, the company obtained CEP certificates for more than ten products. At the same time, the data show that there are more than 100 ongoing research projects in the company, involving many therapeutic fields such as immune system, respiratory system, cardiovascular and cerebrovascular diseases and anti-tumor. All these will provide sustainable growth momentum for the future development of Tianjin Tianyao Pharmaceuticals Co.,Ltd..